Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition

Tissue‐Engineered Disease Modeling of Lymphangioleiomyomatosis Exposes a Therapeutic Vulnerability to HDAC Inhibition

Abstract Lymphangioleiomyomatosis (LAM) is a rare disease involving cystic lung destruction by invasive LAM cells. These cells harbor loss‐of‐function mutations in TSC2, conferring hyperactive mTORC1 signaling. Here, tissue engineering tools are employed to model LAM and identify new therapeutic can...

Full description

Bibliographic Details
Main Authors: Adam Pietrobon, Julien Yockell‐Lelièvre, Nicole Melong, Laura J. Smith, Sean P. Delaney, Nadine Azzam, Chang Xue, Nishanth Merwin, Eric Lian, Alberto Camacho‐Magallanes, Carole Doré, Gabriel Musso, Lisa M. Julian, Arnold S. Kristof, Roger Y. Tam, Jason N. Berman, Molly S. Shoichet, William L. Stanford
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Advanced Science
Subjects:
3D drug screen
biomimetic hydrogel culture
HDAC inhibition
lymphangioleiomyomatosis
mTORC1
therapeutics development
Online Access:https://doi.org/10.1002/advs.202302611

Internet

https://doi.org/10.1002/advs.202302611

Similar Items